The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type.
Chiara TarantelliEleonora CannasHillarie EkehCarmelo MoscatelloEugenio GaudioLuciano CascioneSara NapoliCesare RechAndrea TestaChiara ManiaciAndrea RinaldiEmanuele ZuccaAnastasios StathisAlessio CiulliFrancesco BertoniPublished in: Exploration of targeted anti-tumor therapy (2021)
, it elicited more profound effects than BET inhibitors, and encourages further investigations.